Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Protagonist Therapeutics Inc (PTGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 169,088
  • Shares Outstanding, K 24,190
  • Annual Sales, $ -25,060 K
  • Annual Income, $ 23,640 K
  • 36-Month Beta 3.30
  • Price/Sales 8.09
  • Price/Cash Flow N/A
  • Price/Book 1.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.42
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.67
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -180.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.49 +24.41%
on 11/28/18
9.36 -27.03%
on 11/15/18
-1.51 (-18.11%)
since 11/13/18
3-Month
5.49 +24.41%
on 11/28/18
11.20 -39.02%
on 09/27/18
-1.60 (-18.98%)
since 09/13/18
52-Week
5.49 +24.41%
on 11/28/18
23.97 -71.51%
on 03/09/18
-11.33 (-62.39%)
since 12/13/17

Most Recent Stories

More News
Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the initiation of dosing in the Phase 1 study of PN-10943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide in development...

PTGX : 6.83 (-2.29%)
Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the BMO Capital Markets 2018 Prescriptions...

PTGX : 6.83 (-2.29%)
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company plans to begin clinical development of PN-10943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide for the...

PTGX : 6.83 (-2.29%)
New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group -- Consolidated Revenues, Company Growth, and Expectations for 2018

PTGX : 6.83 (-2.29%)
FPRX : 9.81 (-18.59%)
HMTV : 13.10 (-3.11%)
APEI : 28.60 (-2.69%)
TA : 4.09 (-3.08%)
RRGB : 33.02 (-0.60%)
Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Stifel 2018 Healthcare Conference...

PTGX : 6.83 (-2.29%)
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 5.00% and -3.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?...

PTGX : 6.83 (-2.29%)
Protagonist Therapeutics: 3Q Earnings Snapshot

NEWARK, Calif. (AP) _ Protagonist Therapeutics Inc. (PTGX) on Tuesday reported a loss of $8.7 million in its third quarter.

PTGX : 6.83 (-2.29%)
Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the third quarter ended September 30, 2018, and provided a corporate update on its clinical development programs.

PTGX : 6.83 (-2.29%)
Protagonist Therapeutics (PTGX) Q3 Earnings Preview: What to Know Ahead of the Release

Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTGX : 6.83 (-2.29%)
Report: Developing Opportunities Within Apollo Investment, Ladder Capital, Medpace, MPLX LP, Silicon Laboratories, and Protagonist Therapeutics -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Apollo Investment Corporation...

LADR : 17.26 (+0.35%)
MEDP : 55.66 (-4.98%)
PTGX : 6.83 (-2.29%)
MPLX : 33.71 (+2.21%)
SLAB : 83.53 (-2.13%)
AINV : 14.45 (-1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade PTGX with:

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

2nd Resistance Point 7.18
1st Resistance Point 7.01
Last Price 6.83
1st Support Level 6.74
2nd Support Level 6.64

See More

52-Week High 23.97
Fibonacci 61.8% 16.91
Fibonacci 50% 14.73
Fibonacci 38.2% 12.55
Last Price 6.83
52-Week Low 5.49

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar